Fig. 5: Evaluation of in vivo treatment efficacy of PLX-NP-P-aPD-1@Gel in metastatic 4T1 breast tumor recurrence model.

a Representative bioluminescence images of 4T1 tumor-bearing mice following different treatments on day 0, day 7, day 14, day 21 (n = 6 mice). Saline; NP-P@Gel, blank nanoparticles and unmodified platelets co-loaded hydrogel; PLX-aPD-1@Gel, free PLX and aPD-1 co-loaded hydrogel; PLX-NP@Gel, PLX-NP loaded hydrogel; P-aPD-1@Gel, P-aPD-1 loaded hydrogel; PLX-NP+P-aPD-1, free PLX-NP and P-aPD-1; PLX-NP-P-aPD-1@Gel, PLX-NP and P-aPD-1 co-loaded hydrogel. The dose of PLX and aPD-1 was 5 mg/kg and 0.1 mg/kg, respectively. b Region-of-interest analysis of bioluminescence intensity of the tumors among different treatment groups (PLX-NP-P-aPD-1@Gel vs. PLX-NP+P-aPD-1: ^***P < 0.0001). Data are presented as mean ± s.d. (n = 6 mice) and analyzed with two-way ANOVA followed by Tukey’s multiple comparisons test. c Survival curves of the mice treated with different treatment groups (n = 6 mice). Data were analyzed with Log-rank (Mantel-Cox) test, PLX-NP-P-aPD-1@Gel vs. PLX-NP + P-aPD-1: ^**P = 0.0018. d Quantitative analysis of the number of metastatic nodules on the surface of the lungs on day 21 (PLX-NP-P-aPD-1@Gel vs. PLX-NP@Gel: ^*P = 0.0313; PLX-NP-P-aPD-1@Gel vs. P-aPD-1@Gel: ^*P = 0.0168; PLX-NP-P-aPD-1@Gel vs. PLX-NP+P-aPD-1: ^*P = 0.0215). Data are presented as mean ± s.d. (n = 3 biologically independent samples) and analyzed with one-way ANOVA followed by Dunnett’s multiple comparison test. e Representative images of the lungs after fixation in bouin’s solution and H&E staining after different treatments on day 21 (n = 3 biological independent samples, scale bar = 2 mm). Source data are provided as a Source Data file.